Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians

Harvard Review of Psychiatry

Volumn 24, Issue 2, 2016, Pages 87-103

  Woodberry, Kristen A ^a,b   Shapiro, Daniel I ^a,b   Bryant, Caitlin ^b   Seidman, Larry J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

basic symptoms; clinical high risk; dynamic risk; early intervention; schizophrenia; ultra high risk

Indexed keywords

HYDROCORTISONE; NEUROLEPTIC AGENT;

COGNITION; COGNITIVE DEFECT; EARLY INTERVENTION; GENE EXPRESSION; HELP SEEKING BEHAVIOR; HEREDITY; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; NEUROIMAGING; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSIS PRODROME; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIAL INTERACTION; STRESS; SYMPTOM ASSESSMENT; WHITE MATTER; BRAIN; GENETICS; MEDICAL RESEARCH; META ANALYSIS (TOPIC); PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROTECTION; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRENDS;

BIOMEDICAL RESEARCH; BRAIN; HUMANS; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PROTECTIVE FACTORS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84962550824     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000109     Document Type: Review

References (200)

1. McGorry PD, Yung AR, Phillips LJ,. The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 2003; 29: 771-90.
2. Miller TJ, McGlashan TH, Woods SW,. Symptom assessment in schizophrenic prodromal states. Psychiatr Q 1999; 70: 273-87.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing, 2013.
4. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F,. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158-64.
5. Schultze-Lutter F, Ruhrmann S, Hoyer C, Klosterkötter J, Leweke FM,. The initial prodrome of schizophrenia: different duration, different underlying deficits? Compr Psychiatry 2007; 48: 479-88.
6. Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L,. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res 2011; 132: 8-17.
7. Freedman B, Chapman LJ,. Early subjective experience in schizophrenic episodes. J Abnorm Psychol 1973; 82: 46-54.
8. Gross G, Huber G, Klosterkötter J, Linz M,. BSABS: Bonn Scale for the Assessment of Basic Symptoms, Berlin: Springer, 1987.
9. Häfner H, Maurer K, Löffler W, an der Heiden W, Hambrecht M, Schultze-Lutter F,. Modeling the early course of schizophrenia. Schizophr Bull 2003; 29: 325-40.
10. Dominguez MD, Saka MC, Lieb R, Wittchen HU, van Os J,. Early expression of negative/disorganized symptoms predicting psychotic experiences and subsequent clinical psychosis: a 10-year study. Am J Psychiatry 2010; 167: 1075-82.
11. Woodberry KA, Serur RA, Hallinan SB,. Frequency and pattern of childhood symptom onset reported by first episode schizophrenia and clinical high risk youth. Schizophr Res 2014; 158: 45-51.
12. Gourzis P, Katrivanou A, Beratis S,. Symptomatology of the initial prodromal phase in schizophrenia. Schizophr Bull 2002; 28: 415-29.
13. Yung AR, McGorry PD,. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996; 22: 353-70.
14. Yung AR, Yuen HP, McGorry PD,. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39: 964-71.
15. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J,. Schizophrenia Proneness Instrument, Adult Version (SPI-A). Rome: Giovanni Fioriti, 2007.
16. Schultze-Lutter F,. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 2009; 35: 5-8.
17. Ruhrmann S, Schultze-Lutter F, Salokangas RK,. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 2010; 67: 241-51.
18. Schultze-Lutter F, Schimmelmann BG, Ruhrmann S, Michel C,. A rose is a rose is a rose, but at-risk criteria differ. Psychopathology 2013; 46: 75-87.
19. Fusar-Poli P, Deste G, Smieskova R,. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012; 69: 1-10.
20. Schultze-Lutter F, Michel C, Schmidt SJ,. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry 2015; 30: 405-16.
21. Woods SW, Addington J, Cadenhead KS,. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009; 35: 894-908.
22. Yung AR, Nelson B, Stanford C,. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res 2008; 105: 10-7.
23. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B,. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res 2004; 68: 37-48.
24. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V,. Risk factors for transition to first episode psychosis among individuals with "at-risk mental states." Schizophr Res 2004; 71: 227-37.
25. Addington J, Penn D, Woods SW, Addington D, Perkins DO,. Social functioning in individuals at clinical high risk for psychosis. Schizophr Res 2008; 99: 119-24.
26. Cadenhead KS, Addington J, Cannon T,. Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study cohort. Early Interv Psychiatry 2010; 4: 220-6.
27. Woodberry KA, Addington J, Bearden CE,. Psychosocial treatment prior to identification of clinical high risk status: characteristics of the North American Prodrome Longitudinal Study (NAPLS)-2 cohort. Schizophr Bull 2015; 41 suppl 1: S340.
28. Addington J, Cornblatt BA, Cadenhead KS,. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 2011; 168: 800-5.
29. Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR,. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry 2015; 172: 249-58.
30. Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M,. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 2012; 42: 1857-63.
31. Morgan C, Fisher H, Hutchinson G,. Ethnicity, social disadvantage and psychotic-like experiences in a healthy population based sample. Acta Psychiatr Scand 2009; 119: 226-35.
32. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L,. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 2009; 39: 179-95.
33. Hanssen M, Bak M, Bijl R, Vollebergh W, van Os J,. The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol 2005; 44: 181-91.
34. Kaymaz N, Drukker M, Lieb R,. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. Psychol Med 2012; 42: 2239-53.
35. Nelson B, Yuen HP, Wood SJ,. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study. JAMA Psychiatry 2013; 70: 793-802.
36. Cannon TD, Cadenhead K, Cornblatt B,. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65: 28-37.
37. Schimmelmann BG, Walger P, Schultze-Lutter F,. The significance of at-risk symptoms for psychosis in children and adolescents. Can J Psychiatry 2013; 58: 32-40.
38. Calkins ME, Moore TM, Merikangas KR,. The psychosis spectrum in a young U.S. community sample: findings from the Philadelphia Neurodevelopmental Cohort. World Psychiatry 2014; 13: 296-305.
39. Schimmelmann BG, Michel C, Martz-Irngartinger A, Linder C, Schultze-Lutter F,. Age matters in the prevalence and clinical significance of ultra-high-risk for psychosis symptoms and criteria in the general population: findings from the BEAR and BEARS-kid studies. World Psychiatry 2015; 14: 189-97.
40. Crlenjak C, Ratheesh A, Blaikie S, Dodd S, Hughes A, Simpson R,. Let me understand: assessment in early psychosis. Melbourne: Orygen Youth Health Research Center, 2014.
41. Tsuang MT, Stone WS, Faraone SV,. Genes, environment and schizophrenia. Br J Psychiatry Suppl 2001; 40: s18-24.
42. Tienari P, Wynne LC, Moring J,. The Finnish adoptive family study of schizophrenia: implications for family research. Br J Psychiatry 1994; 164: 20-6.
43. Kendler KS, Diehl SR,. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull 1993; 19: 261-85.
44. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421-7.
45. Kraepelin E,. Dementia praecox and paraphrenia. Edinburgh: E S Livingston, 1919.
46. Bleuler E,. Dementia praecox or the group of schizophrenias, New York: International Universities, 1950.
47. Heinrichs RW, Zakzanis KK,. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998; 12: 426-45.
48. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ,. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009; 23: 315-36.
49. Walker EF, Savoie T, Davis D,. Neuromotor precursors of schizophrenia. Schizophr Bull 1994; 20: 441-51.
50. Cannon TD, Bearden CE, Hollister JM, Rosso IM, Sanchez LE, Hadley T,. Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull 2000; 26: 379-93.
51. Cannon M, Caspi A, Moffit TE,. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder. Arch Gen Psychiatry 2002; 59: 449-56.
52. Dickson H, Laurens KR, Cullen AE, Hodgins S,. Meta-analyses of cognitive and motor function in youth aged 16 and younger who subsequently developed schizophrenia. Psychol Med 2011; 42: 743-55.
53. Woodberry KA, Giuliano AJ, Seidman LJ,. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry 2008; 165: 579-87.
54. Giuliano AJ, Li H, Mesholam-Gately RI, Sorenson SM, Woodberry KA, Seidman LJ,. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharm Des 2012; 18: 399-415.
55. Agnew-Blais J, Seidman LJ,. Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: a quantitative and qualitative review. Cogn Neuropsychiatry 2013; 18: 44-82.
56. Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV,. Neuropsychological risk indicators for schizophrenia: a review of family studies. Schizophr Bull 1994; 20: 96-108.
57. Agnew-Blais JC, Buka SL, Fitzmaurice GM, Smoller JW, Goldstein JM, Seidman LJ,. Early childhood IQ trajectories of adults with schizophrenia and affective psychoses in the New England Family Studies. Schizophr Bull 2015; 41: 817-23.
58. Seidman LJ, Cherkerzian S, Goldstein JM, Agnew-Blais J, Tsuang MT, Buka SL,. Neuropsychological performance and family history in children at age 7 who develop adult schizophrenia or bipolar psychosis in the New England High-Risk Family Study. Psychol Med 2013; 43: 119-31.
59. Reichenberg A, Caspi A, Harrington H,. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry 2010; 167: 160-9.
60. Fuller R, Nopoulos P, Arndt S, OLeary D, Ho BC, Andreasen NC,. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized test performance. Am J Psychiatry 2002; 159: 1183-9.
61. MacCabe JH, Wicks S, Lofving S,. Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males. JAMA Psychiatry 2013; 70: 261-70.
62. Seidman LJ, Giuliano AJ, Meyer EC,. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010; 67: 578-88.
63. Cornblatt BA, Carrión RE, Auther A,. Psychosis prevention: a modified clinical high risk perspective from the Recognition and Prevention (RAP) Program. Am J Psychiatry 2015; 172: 986-94.
64. Carrión RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, Cornblatt BA,. Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J Psychiatry 2011; 168: 806-13.
65. Meyer EC, Carrion RE, Cornblatt BA,. The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in NAPLS-1. Schizophr Bull 2014; 40: 1452-61.
66. Becker HE, Nieman DH, Wiltink S,. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration? Psychol Med 2010; 40: 1599-606.
67. Woodberry KA, McFarlane WR, Giuliano AJ,. Change in neuropsychological functioning over one year in youth at clinical high risk for psychosis. Schizophr Res 2013; 146: 87-94.
68. Addington J, Barbato M,. Social cognition in those at high risk of psychosis. In: Schutt RK, Seidman LJ, Keshavan MS,., eds. Social neuroscience: brain, mind, and society. Cambridge, MA: Harvard University Press, 2015.
69. Tarbox SI, Pogue-Geile MF,. Development of social functioning in preschizophrenia children and adolescents: a systematic review. Psychol Bull 2008; 134: 561-83.
70. Cornblatt BA, Carrión RE, Addington J,. Risk factors for psychosis: impaired social and role functioning. Schizophr Bull 2012; 38: 1247-57.
71. Lin A, Wood SJ, Nelson B,. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res 2011; 132: 1-7.
72. Salokangas RK, Nieman DH, Heinimaa M,. Psychosocial outcome in patients at clinical high risk of psychosis: a prospective follow-up. Soc Psychiatry Psychiatr Epidemiol 2013; 48: 303-11.
73. Brent BK, Thermenos HW, Keshavan MS, Seidman LJ,. Gray matter alterations in schizophrenia high-risk youth and early-onset schizophrenia: a review of structural MRI findings. Child Adolesc Psychiatr Clin N Am 2013; 22: 689-714.
74. Thermenos HW, Keshavan MS, Juelich RJ,. A review of neuroimaging studies of young relatives of persons with schizophrenia: a developmental perspective from schizotaxia to schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2013; 162: 604-35.
75. Dazzan P, Soulsby B, Mechelli A,. Volumetric abnormalities predating the onset of schizophrenia and affective psychoses: an MRI study in subjects at ultrahigh risk of psychosis. Schizophr Bull 2012; 38: 1083-91.
76. Koutsouleris N, Gaser C, Bottlender R,. Use of neuroanatomical pattern regression to predict the structural brain dynamics of vulnerability and transition to psychosis. Schizophr Res 2010; 123: 175-87.
77. Iwashiro N, Suga M, Takano Y,. Localized gray matter volume reductions in the pars triangularis of the inferior frontal gyrus in individuals at clinical high-risk for psychosis and first episode for schizophrenia. Schizophr Res 2012; 137: 124-31.
78. Pantelis C, Velakoulis D, McGorry PD,. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003; 361: 281-8.
79. Sun D, Phillips L, Velakoulis D,. Progressive brain structural changes mapped as psychosis develops in at risk individuals. Schizophr Res 2009; 108: 85-92.
80. Takahashi T, Wood SJ, Yung AR,. Insular cortex gray matter changes in individuals at ultra-high-risk of developing psychosis. Schizophr Res 2009; 111: 94-102.
81. Takahashi T, Wood SJ, Yung AR,. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch Gen Psychiatry 2009; 66: 366-76.
82. Ziermans TB, Schothorst PF, Schnack HG,. Progressive structural brain changes during development of psychosis. Schizophr Bull 2012; 38: 519-30.
83. Borgwardt SJ, McGuire PK, Aston J,. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res 2008; 106: 108-14.
84. Walter A, Studerus E, Smieskova R,. Hippocampal volume in subjects at high risk of psychosis: a longitudinal MRI study. Schizophr Res 2012; 142: 217-22.
85. Cannon TD, Chung Y, He G,. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry 2015; 77: 147-57.
86. Anderson G, Berk M, Dodd S,. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 1-4.
87. Flatow J, Buckley P, Miller BJ,. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013; 74: 400-9.
88. Schwarz E, Guest PC, Rahmoune H,. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012; 17: 494-502.
89. Kirkpatrick B, Miller BJ,. Inflammation and schizophrenia. Schizophr Bull 2013; 39: 1174-9.
90. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B,. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-71.
91. Steullet P, Cabungcal JH, Monin A,. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a "central hub" in schizophrenia pathophysiology? Schizophr Res 2014. Jul 4 [Epub ahead of print].
92. Pasternak O, Westin CF, Bouix S,. Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset. J Neurosci 2012; 32: 17365-72.
93. Perkins DO, Jeffries CD, Addington J,. Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull 2015; 41: 419-28.
94. Trotman HD, Holtzman CW, Walker EF,. Stress exposure and sensitivity in the clinical high-risk syndrome: initial findings from the North American Prodrome Longitudinal Study (NAPLS). Schizophr Res 2014; 160: 104-9.
95. Shevlin M, Houston JE, Dorahy MJ, Adamson G,. Cumulative traumas and psychosis: an analysis of the national comorbidity survey and the British Psychiatric Morbidity Survey. Schizophr Bull 2008; 34: 193-9.
96. Galletly C, Van Hooff M, McFarlane A,. Psychotic symptoms in young adults exposed to childhood trauma-a 20 year follow-up study. Schizophr Res 2011; 127: 76-82.
97. Holtzman CW, Trotman HD, Goulding SM,. Stress and neurodevelopmental processes in the emergence of psychosis. Neuroscience 2013; 249: 172-91.
98. Schlosser DA, Pearson R, Perez VB, Loewy RL,. Environmental risk and protective factors and their influence on the emergence of psychosis. Adolesc Psychiatry (Hilversum) 2012; 2: 163-71.
99. Aiello G, Horowitz M, Hepgul N, Pariante CM, Mondelli V,. Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with "at risk" mental state. Psychoneuroendocrinology 2012; 37: 1600-13.
100. Thompson KN, Berger G, Phillips LJ, Komesaroff P, Purcell R, McGorry PD,. HPA axis functioning associated with transition to psychosis: combined DEX/CRH test. J Psychiatr Res 2007; 41: 446-50.
101. Walker EF, Brennan PA, Esterberg M, Brasfield J, Pearce B, Compton MT,. Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth. J Abnorm Psychol 2010; 119: 401-8.
102. Mizrahi R, Addington J, Rusjan PM,. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 2012; 71: 561-7.
103. Walker E, Trotman H, Pearce B,. Cortisol levels and risk for psychosis: initial findings from the North American Longitudinal Study. Biol Psychiatry 2013; 74: 410-7.
104. Cardno AG, Marshall EJ, Coid B,. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999; 56: 162-8.
105. Brown AS,. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011; 93: 23-58.
106. Torrey EF, Miller J, Rawlings R, Yolken RH,. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 1997; 28: 1-38.
107. Torrey EF, Burka S, Cannon TD,. Paternal age as a risk factor for schizophrenia: how important is it? Schizophr Res 2009; 111: 1-5.
108. Saha S, Chant D, Welham J, McGrath J,. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
109. March D, Hatch SL, Morgan C,. Psychosis and place. Epidemiol Rev 2008; 30: 84-100.
110. Pedersen CB, Mortensen PB,. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch Gen Psychiatry 2001; 58: 1039-46.
111. Cantor-Graae E, Selten JP,. Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry 2005; 162: 12-24.
112. Boydell J, Van Os J, McKenzie K,. Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment. BMJ 2001; 323: 1336-8.
113. Tienari P, Wynne LC, Sorri A,. Genotype-environment interaction in schizophrenia-spectrum disorder long-term follow-up study of Finnish adoptees. Br J Psychiatry 2004; 184: 216-22.
114. Hooley JM, Woodberry KA, Ferriter C,. Family factors in schizophrenia and bipolar disorder. In: Hudson JL, Rapee RM,., eds. Psychopathology and the family. Boston: Elsevier, 2005.
115. Krabbendam L, van Os J,. Schizophrenia and urbanicity: a major environmental influence-conditional on genetic risk. Schizophr Bull 2005; 31: 795-9.
116. Tsuang M,. Schizophrenia: genes and environment. Biol Psychiatry 2000; 47: 210-20.
117. Andréasson S, Allebeck P, Engström A, Rydberg U,. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-6.
118. Gururajan A, Manning EE, Klug M, van den Buuse M,. Drugs of abuse and increased risk of psychosis development. Aust N Z J Psychiatry 2012; 46: 1120-35.
119. Arseneault L, Cannon M, Witton J, Murray RM,. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110-7.
120. Addington J, Case N, Saleem MM,. Substance use in clinical high risk for psychosis: a review of the literature. Early Interv Psychiatry 2014; 8: 104-12.
121. Auther AM, Cadenhead KS, Carrion RE,. Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. Acta Psychiatr Scand 2015; 132: 60-8.
122. Valmaggia LR, Day FL, Jones C,. Cannabis use and transition to psychosis in people at ultra-high risk. Psychol Med 2014; 44: 2503-12.
123. Schvarcz A, Bearden CE,. Early detection of psychosis: recent updates from clinical high-risk research. Curr Behav Neurosci Rep 2015; 2: 90-101.
124. Mäki P, Veijola J, Jones PB,. Predictors of schizophrenia-a review. Br Med Bull 2005; 73: 1-15.
125. Schlosser DA, Zinberg JL, Loewy RL,. Predicting the longitudinal effects of the family environment on prodromal symptoms and functioning in patients at-risk for psychosis. Schizophr Res 2010; 118: 69-75.
126. OBrien MP, Gordon JL, Bearden CE, Lopez SR, Kopelowicz A, Cannon TD,. Positive family environment predicts improvement in symptoms and social functioning among adolescents at imminent risk for onset of psychosis. Schizophr Res 2006; 81: 269-75.
127. Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B,. A role for estrogen in schizophrenia: clinical and preclinical findings. Int J Endocrinol. 2015 Sep 27 [Epub].
128. Bell RQ,. Multiple-risk cohorts and segmenting risk as solutions to the problem of false positives in risk for the major psychoses. Psychiatry 1992; 55: 370-81.
129. Ruhrmann S, Schultze-Lutter F, Schmidt SJ, Kaiser N, Klosterkötter J,. Prediction and prevention of psychosis: current progress and future tasks. Eur Arch Psychiatry Clin Neurosci 2014; 264 suppl 1: S9-16.
130. Yang LH, Wonpat-Borja AJ, Opler MG, Corcoran CM,. Potential stigma associated with inclusion of psychosis risk syndrome in the DSM-V: an empirical question. Schizophr Res 2010; 120: 42-8.
131. Yung AR, Yuen HP, Berger G,. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007; 33: 673-81.
132. McGorry PD, Nelson B, Goldstone S, Yung AR,. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry 2010; 55: 486-97.
133. Fusar-Poli P, Borgwardt S, Bechdolf A,. The psychosis high-risk state. A comprehensive state-of-the-art review. JAMA Psychiatry 2013; 70: 107-20.
134. Schultze-Lutter F, Klosterkötter J, Ruhrmann S,. Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophr Res 2014; 154: 100-6.
135. Ruhrmann S, Schultze-Lutter F, Klosterkötter J,. Probably at-risk, but certainly ill-advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 2010; 120: 23-37.
136. Thompson A, Nelson B, Yung A,. Predictive validity of clinical variables in the "at risk" for psychosis population: international comparison with results from the North American Prodrome Longitudinal Study. Schizophr Res 2011; 126: 51-7.
137. Yung AR, Phillips LJ, Yuen HP, McGorry PD,. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004; 67: 131-42.
138. Riecher-Rössler A, Pflueger MO, Aston J,. Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry 2009; 66: 1023-30.
139. Koutsouleris N, Borgwardt S, Meisenzahl EM, Bottlender R, Möller HJ, Riecher-Rössler A,. Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. Schizophr Bull 2012; 38: 1234-46.
140. Koutsouleris N, Davatzikos C, Bottlender R,. Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification. Schizophr Bull 2012; 38: 1200-15.
141. Nieman DH, Ruhrmann S, Dragt S,. Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. Schizophr Bull 2013; 40: 1482-90.
142. Perkins DO, Jeffries CD, Addington J,. Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS Project. Schizophr Bull 2015; 41: 419-28.
143. Cannon TD,. Biomarkers of vulnerability and progression in the psychosis prodrome. Oral session conducted at the 15th annual International Congress on Schizophrenia Research, Colorado Springs, CO, March 2015.
144. Clark SR, Schubert KO, Baune B,. Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome. J Neural Transm (Vienna) 2015; 122: 155-69.
145. Preti A, Cella M,. Randomized-controlled trials in people at ultra-high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010; 123: 30-6.
146. van der Gaag M, Smit F, Bechdolf A,. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 months and longer-term follow-ups. Schizophr Res 2013; 149: 56-62.
147. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T,. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013; 346: f185.
148. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG,. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 2015; 30: 388-404.
149. Marshall M, Rathbone J,. Early intervention for psychosis. Schizophr Bull 2011; 37: 1111-4.
150. Heinssen RK, Insel TR,. Preventing the onset of psychosis: not quite there yet. Schizophr Bull 2015; 41: 28-9.
151. McGorry PD, Yung AR, Phillips LJ,. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-8.
152. McGorry PD, Nelson B, Phillips LJ,. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry 2013; 74 (4): 349-56.
153. McGlashan TH, Zipursky RB, Perkins D,. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-9.
154. Amminger GP, Schafer MR, Papageorgiou K,. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-54.
155. Morrison AP, French P, Walford L,. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004; 185: 291-7.
156. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB,. A randomized controlled trial of cognitive-behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011; 125: 54-61.
157. Morrison AP, French P, Stewart SL,. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 2012; 5: e2233.
158. van der Gaag M, Nieman DH, Rietdijk J,. Cognitive-behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 2012; 38: 1180-8.
159. Bechdolf A, Wagner M, Ruhrmann S,. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 2012; 200: 22-9.
160. Miklowitz DJ, OBrien MP, Schlosser DA,. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry 2014; 53: 848-58.
161. Nordentoft M, Thorup A, Petersen L,. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006; 83: 29-40.
162. Piskulic D, Barbato M, Liu L, Addington J,. Pilot study of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Psychiatry Res 2015; 225: 93-8.
163. Woods SW, Addington J, Bearden CE,. Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. Schizophr Res 2013; 148: 99-104.
164. Bryant C, Woodberry KA, Seidman LJ,. Disclosing a developing disorder: sharing symptoms vs. diagnoses by youth at high risk for psychosis. Poster presented at the Harvard Medical School Department of Psychiatry Research Day, Boston, MA, March 2015.
165. McFarlane WR, Levin B, Travis L,. Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. Schizophr Bull 2015; 41: 30-43.
166. Holzer L, Urben S, Passini CM,. A randomized controlled trial of the effectiveness of Computer-Assisted Cognitive Remediation (CACR) in adolescents with psychosis or at high risk of psychosis. Behav Cogn Psychother 2014; 42: 421-34.
167. Hooker CI, Carol EE, Eisenstein TJ,. A pilot study of cognitive training in clinical high risk for psychosis: initial evidence of cognitive benefit. Schizophr Res 2014; 157: 314-6.
168. Rauchensteiner S, Kawohl W, Ozgurdal S,. Test-performance after cognitive training in persons at risk mental state of schizophrenia and patients with schizophrenia. Psychiatry Res 2011; 185: 334-9.
169. Green MF, Kern RS, Braff DL, Mintz J,. Neurocognitive deficits and functional outcome in schizophrenia. Schizophr Bull 2000; 26: 119-36.
170. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P,. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011; 168: 472-85.
171. Keshavan MS, Vinogradov S, Rumsey J, Sherrill J, Wagner A,. Cognitive training in mental disorders: update and future directions. Am J Psychiatry 2014; 171: 510-22.
172. McGorry P, Markulev C, Nelson B,. The NEURAPRO-E study: a multicenter RCT of omega-3 fatty acids and cognitive-behavioral case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Schizophr Bull 2015; 41 suppl 1: S322-3.
173. Council of Australian Governments. Roadmap for national mental health reform. 2012. http://www.coag.gov.au/node/482
174. Birchwood M, Connor C, Leste H,. Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. Br J Psychiatry 2013; 203: 58-64.
175. Substance Abuse and Mental Health Services Administration. Now is the time-prevention and early intervention: healthy transitions. 2015. http://www.samhsa.gov/priorities/now-is-the-time
176. Ruhrmann S, Bechdolf A, Kuhn KU,. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 2007; 51: s96-101.
177. Woods SW, Tully EM, Walsh BC,. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 2007; 51: s96-101.
178. Cornblatt BA, Lencz T, Smith CW,. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007; 68: 546-57.
179. Woods SJ, Berger GE, DellOlio M,. Effects of low dose lithium on hippocampal neuropathology in people at ultra-high risk for psychosis. Biol Psychiatry 2007; 61: 259s-60.
180. Woods SW, Walsh BC, Hawkins KA,. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol 2013; 23: 931-40.
181. ClinicalTrials.gov. Randomized controlled trial of aspirin vs placebo in the treatment of pre-psychosis. https://www.clinicaltrials.gov/ct2/results?term=NCT02047539
182. Kantrowitz JT, Woods SW, Petkova E,. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry 2015; 2: 403-12.
183. Schlosser D, Kim D, Campellone T, Ward C, Vinogradov S,. PRIME: a neuroscience-informed mobile app intervention to treat reward processing impairments and improve quality of life in recent onset schizophrenia. Schizophr Bull 2015; 41 suppl 1: S332.
184. Mittal VA,. Exercise-based cognitive remediation for youth at ultra high-risk for psychosis. Schizophr Bull 2015; 41 suppl 1: S324-5.
185. Woodberry KA, Serur RA, Hallinan S,. Integrating biofeedback games and family therapy to reduce risk for psychosis. Poster presented at the Harvard Medical School Department of Psychiatry Research Day, Boston, MA, March 2014.
186. Dixon LB, Dickerson F, Bellack AS,. The 2009 Schizophrenia PORT treatment recommendations and summary statements. Schizophr Bull 2010; 36: 48-70.
187. Francey SM, Nelson B, Thompson A,. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res 2010; 119: 1-10.
188. Yang LH, Link BC, Ben-David S,. Stigma related to labels and symptoms to individuals at clinical high-risk for psychosis. Schizophr Res 2015; 168: 9-15.
189. Marshall M, Rathbone J,. Early intervention for psychosis. Cochrane Database Syst Rev 2011; 6: CD004718.
190. Cochrane. Early intervention for psychosis. 2011. http://www.cochrane.org/CD004718/SCHIZ-early-intervention-for-psychosis
191. National Institute for Health and Clinical Excellence. Psychosis and schizophrenia. https://www.nice.org.uk/guidance/conditions-and-diseases/mental-health-and-behavioural-conditions/psychosis-and-schizophrenia
192. Deutsche Geselleschaft fur Psychiatrie, Psychotherapie und Nervenheilkunde. Behandlungsleitlinie Schizophrenie. Darmstadt, Germany: Steinkopff Verlag, 2006.
193. Kohler C, Borgmann-Winter KE, Huford I, Neustadter E, Yi J, Calkins ME,. Is prevention a realistic goal for schizophrenia? Curr Psychiatry Rep 2014; 16: 439.
194. Nelson B, Hughes A, Leicester S,. A stitch in time: interventions for young people at ultra high risk of psychosis. Melbourne: Orygen Youth Health Research Centre, 2014.
195. Singh F, DeJoseph M, Cadenhead KS,. Therapeutic considerations in individuals at clinical risk for developing psychosis. Fortschr Neurol Psychiatr 2012; 80: 570-9.
196. Sullivan HS,. The onset of schizophrenia. Am J Psychiatry 1927; 7: 105-34.
197. Okkels N, Vernal DL, Jensen SOW, McGrath JJ, Nielsen RE,. Changes in the diagnosed incidence of early onset schizophrenia over four decades. Acta Psychiatr Scand 2013; 127: 62-8.
198. Davidson RJ, McEwen BS,. Social influences on neuroplasticity: stress and interventions to promote well-being. Nat Neurosci 2012; 15: 689-95.
199. Sandi C, Haller J,. Stress and the social brain: behavioural effects and neurobiological mechanisms. Nat Rev Neurosci 2015; 16: 290-304.
200. McGorry PD,. Evidence based reform of mental health care. BMJ 2005; 331: 586-7.